Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood ...

Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial ...

Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...

FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for ...

FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while ...

A multicomponent approach to vaccination distress works across the lifespan, though how it works depends on age, according to ...

In "Shared Decision-Making for Agitation in Specialty Care and Disease Trajectory," our experts close out the discussion of ...

Many patients with atrial fibrillation (AFib) are not receiving any therapy to prevent stroke, and Geoffrey Barnes, MD, ...

The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication ...

Adults with overweight or obesity who switched from injectable semaglutide or tirzepatide to once-daily oral semaglutide (Wegovy) lost an average of 4.1% of body weight over 3 mon ...

The faculty compare testing strategies across clinical and pharmacy settings. This episode, "HIV Testing Before and During PrEP: Getting It Right," features the faculty walking through baseline and ...

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight ...